Use of a screening authorization and randomization center for severe sepsis patient qualification and real-time enrollment in a phase 2 trial of eritoran tetrasodium (E5564), a TLR4 antagonist

J Schentag; S Opal; M Lynn; A Wittek; J Wheeler

首页> 外文期刊>Critical care : >Use of a screening authorization and randomization center for severe sepsis patient qualification and real-time enrollment in a phase 2 trial of eritoran tetrasodium (E5564), a TLR4 antagonist

【24h】

Use of a screening authorization and randomization center for severe sepsis patient qualification and real-time enrollment in a phase 2 trial of eritoran tetrasodium (E5564), a TLR4 antagonist

机译：使用筛查授权和随机化中心进行严重败血症患者的资格鉴定和实时注册TLR4拮抗剂Eritoran四钠（E5564）的2期临床试验

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Critical care :》 |2009年第4期|共页
作者
J Schentag; S Opal; M Lynn; A Wittek; J Wheeler;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类护理学;
关键词

相似文献

外文文献

1. Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis. [J] . Tidswell M, Tillis W, Larosa SP, Critical care medicine . 2010,第1期

机译：严重脓毒症患者使用Eritoran四钠（E5564）（一种收费型受体4拮抗剂）的2期试验。
2. Influence of severity of illness on the effects of eritoran tetrasodium (E5564), a TLR4 antagonist, in patients with severe sepsis [J] . SM Opal, AC Kalil, SP LaRosa, Critical care : . 2009,第Suppla4期

机译：严重程度对患有严重败血症的患者的ELR4拮抗剂依立托仑四钠（E5564）的影响
3. Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe Sepsis The ACCESS Randomized Trial [J] . Steven M. Opal, Pierre-Francois Laterre, Bruno Francois, JAMA: the Journal of the American Medical Association . 2013,第11期

机译：MD2-TLR4拮抗剂Eritoran对严重脓毒症患者死亡率的影响ACCESS随机试验
4. Use of a screening authorization and randomization center for severe sepsis patient qualification and real-time enrollment in a phase 2 trial of eritoran tetrasodium (E5564) a TLR4 antagonist [O] . J Schentag, S Opal, M Lynn, 2009

机译：使用筛选授权和随机化中心进行严重败血症患者的资格鉴定和实时注册作为TLR4拮抗剂Eritoran四钠（E5564）的2期试验
5. Use of a screening authorization and randomization center for severe sepsis patient qualification and real-time enrollment in a phase 2 trial of eritoran tetrasodium (E5564), a TLR4 antagonist [O] . Schentag, J, Opal, S, Lynn, M, 2009

机译：使用筛选授权和随机化中心进行严重败血症患者的资格鉴定和实时注册，作为TLR4拮抗剂Eritoran四钠（E5564）的2期试验

Use of a screening authorization and randomization center for severe sepsis patient qualification and real-time enrollment in a phase 2 trial of eritoran tetrasodium (E5564), a TLR4 antagonist

著录项

相似文献

相关主题

期刊订阅